Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Technical University of Denmark

Headquarters: Hovedstaden, Denmark
Year Founded: 1829
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Jan 28, 2025
Distillery Therapeutics

De novo-designed antivenom for snakebite

BioCentury | May 3, 2023
Distillery Therapeutics

Alpha neutrotoxin-binding mAb for venomous snake bites

BioCentury | Sep 8, 2022
Discovery & Translation

An inroad to bunyaviruses; plus a gene therapy for tyrosinemia and more

BioCentury’s roundup of translational news
BioCentury | Apr 29, 2022
Discovery & Translation

Cleavage resistant, regulatable CARs; plus Repertoire, Merus and more

BioCentury’s roundup of translational news
BioCentury | Sep 30, 2020
Product Development

Sept. 29 Quick Takes: Ironwood reduces headcount following Phase III miss; plus Sandoz, Catalyst, Myovant, Orphazyme, Synklino, WHO, BridgeBio, Kurma, Junshi, Arcutis, Genfit-LabCorp and GSK

Ironwood to downsize after Phase III GERD failureIronwood Pharmaceuticals Inc. (NASDAQ:IRWD) said it plans to discontinue development of IW-3718 after the therapy missed the primary endpoint in a
BioCentury | May 16, 2019
Emerging Company Profile

SNIPR: Turning CRISPR into a microbiome suicide

Occupying the intersection of the microbiome and CRISPR, SNIPR treats disease by using gene editing to alter gut bacterial populations
BioCentury | Mar 15, 2019
Finance

SNIPR targets the microbiome

How SNIPR's CRISPR microbiome IP drew Lundbeckfonden Emerge, LSP for $50M A round
BioCentury | Apr 10, 2018
Company News

Management tracks: Immunomedics, argenx

BioCentury | Feb 12, 2009
Tools & Techniques

PLAying with liposomes

Items per page:
1 - 10 of 18
Username